download PDF - Newron

More documents

Recommendations

Info

Information for Investors Stock exchange information Symbol NWRN Listing SIX Nominal value EUR 0.20 ISIN IT0004147952 Swiss Security Number (Valor) 002791431 Share price data FY 2011 FY 2010 Number of fully paid-in shares as at December 31 7,264,378 7,264,378 Year high (in CHF) 8.7 23.6 Year low (in CHF) 1.68 5.0 Year-end (in CHF) 2.2 5.7 Loss per share (in EUR) 0.89 3.11 Cash and cash equivalents, other short-term financial assets as at December 31 (in EUR 1,000) 5,367 8,087 Market capitalization as at December 31 (in CHF) 15,981,632 41,261,667 Major shareholders* Great Point Partners 3i Group plc NWB Investissements S.p.r.l. TVM Life Science Ventures VI GmbH & Co. KG Orbimed Aviva Life & Pensions UK Ltd. * With holdings of more than 3% (to the best of the Company’s knowledge) 8 Newron Annual Report 2011
Financial calendar May 31, 2012 June 28, 2012 September 10, 2012 Year-end results 2011 Annual General Meeting, Milan Half-year results 2012 Contact Stefan Weber – CFO Newron Pharmaceuticals S.p.A. Via Ludovico Ariosto 21 20091 Bresso (Mi), Italy Phone +39 02 6103 4630 ir@newron.com Information for Investors – Newron Annual Report 2011 9
Page 1 and 2: Annual Report 2011
Page 3: Key Corporate Events Completion of
Page 6 and 7: Shareholders’ Letter Rolf Stahel
Page 8 and 9: Drug Portfolio Safinamide Adjunctiv
Page 13 and 14: Corporate Governance
Page 15 and 16: Group Structure and Shareholders Ne
Page 17 and 18: To the best of Newron’s knowledge
Page 19 and 20: ight by the Company’s current sha
Page 21 and 22: Stock-based remuneration (stock opt
Page 23 and 24: Rolf Stahel has been the Chairman o
Page 25 and 26: Responsibilities and organization P
Page 27 and 28: Subcommittees The Board has formed
Page 29 and 30: Senior Management Members of the se
Page 31 and 32: Compensation, Shareholdings and Loa
Page 33 and 34: The total gross compensation and th
Page 35 and 36: Attendance and voting rights To att
Page 37 and 38: Auditors Upon proposal by the manag
Page 39: Information Policy Newron undertake
Page 42 and 43: Consolidated Statement of Income (I
Page 44 and 45: Consolidated Statement of Changes i
Page 46 and 47: Notes to the Consolidated Financial
Page 48 and 49: The following new standards, amendm
Page 50 and 51: (‘the functional currency’). Th
Page 52 and 53: P Share capital Ordinary shares and
Page 54 and 55: The Group did not enter into foreig
Page 56 and 57: sell of the property, plant and equ
Page 58 and 59: Other expenses increased by EUR 1,4
Page 60 and 61:
14 Intangible assets (In thousand e
Page 62 and 63:
Government grants receivable includ
Page 64 and 65:
A summary of the granted options is
Page 66 and 67:
Amounts recognized under staff cost
Page 68 and 69:
29 Financial instruments by categor
Page 70 and 71:
Auditors’ Report 68 Newron Annual
Page 72 and 73:
Glossary Activities of Daily Living
Page 74 and 75:
In vitro A biological or chemical p
Page 76 and 77:
Product Candidate (or Clinical Comp
Page 78:
Imprint Publisher Newron Pharmaceut
show all

download PDF - Newron

Create successful ePaper yourself

Delete template?

Save as template?